• VerImmune

  Led · Series A · Sep 2024

  VerImmune is developing a virus-inspired particle (ViP™) platform that enables a first-in-class cancer immunotherapy approach called anti-tumor immune redirection (AIR). The AIR approach harnesses patients’ pre-existing immune memory from past infections or childhood vaccinations to redirect immune responses against tumors. The company’s primary focus is oncology, aiming to offer new treatment options for patients with limited responses to current therapies. Led by Founder and CEO Dr. Joshua Wang, VerImmune plans to use the financing to expand operations and advance development efforts of its ViP platform. The company recently strengthened its board with the additions of Dr. Che Hsu (General Manager of Beiley) and Dr. Marta New (CEO of Radyus Research) as an independent director. VerImmune is an early-stage biotechnology company based in Washington, DC, developing products from a novel Virus-inspired Particle (ViP™) technology platform. Its lead immuno-oncology candidate, VERI-101, uses the ViP platform to harness pre-existing cellular immune memory from prior cytomegalovirus (CMV) infection in an approach the company calls Anti-tumor Immune Redirection (AIR). AIR is positioned as a potential first-in-class cancer immunotherapy that could be used as a stand-alone treatment or in combination with other immunotherapies for patients with untreatable cancers or resistance to existing therapies. VerImmune plans to use the recent financing to accelerate GLP/GMP activities toward an IND for VERI-101. The company is led by founder and CEO Joshua Wang. Financially, VerImmune raised an additional $3.125 million from a follow-on Seed financing and a partnership milestone payment to support development and process activities. VerImmune is an early-stage biotechnology company developing a first-in-class cancer therapy called Anti-tumor Immune Redirection (AIR). The AIR strategy uses a proprietary virus-inspired particle (ViP) platform to redirect pre-existing pathogenic or childhood vaccine immune memory toward tumors. The company is led by CEO Joshua Wang and COO John Troyer. VerImmune plans to use the financing to accelerate its lead product development timelines and to grow its team. Founded in early 2020, the company operated near Johns Hopkins East Baltimore Campus and in early 2022 moved its research laboratories to Johnson & Johnson Innovation – JLABS @ Washington, DC. The company states its laboratory headquarters remain within the BioHealth Capital Region cluster.

No current team members are available.